📅 PUBMED DAILY TRIAGE — 2026-10-23

Window: 2026-10-22T09:00:00Z → 2026-10-23T09:00:00Z (CRDT) Topics scanned: 9 watchlist + 1 sentinel | Articles reviewed: ~100 candidates across topics | Kept: 23 High priority: 3 | Standard: 20 | Low/archive: 0 | Unsolicited finds: 1 Run status: PARTIAL_SUCCESS (T3/T4/T5/T6/T7/T8 partially reviewed; T1/T2/T9 complete)

🔴🟠 HIGH PRIORITY (8+, or flagged) — Best Finds by Topic

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

PMID-42908017 · Early and accurate detection of ovarian cancer by profiling cell-free mitochondrial DNA fragmentomics in multi-ethnic population · 9/10 · 🔴 EARLY_CANCER_DETECTION Novel ccf-mtDNA fragmentomics ML model achieves AUC 0.987 and 91.67% Stage I sensitivity at 95% specificity across multi-ethnic, multi-center validation cohorts — one of the strongest liquid biopsy results yet for early ovarian cancer detection. (Genome Med; Guo X et al.)

Hematologic Malignancies (AML, MDS, CLL, MPN, lymphoma)

PMID-42902921 · Patient-specific genomic measurable residual disease markers for monitoring AML and myeloid malignancy · 9/10 · 🟢 NEAR_TERM_IMPLEMENTABLE Patient-specific PCR-MRD assays from WGS/NGS succeeded in 97.6% of myeloid malignancy patients in a multi-center Australian prospective study, with higher sensitivity than ALL MRD and outcome correlation — directly closes the gap in universal AML MRD monitoring. (Br J Haematol; Huang L et al.)

PMID-42906182 · Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas · 4/10 → HIGH · 🟠 NOVEL_TREATMENT 100% ORR and 89% CR in n=9 r/r CNS lymphoma patients (including Burkitt and TP53-mutant MCL) with rapid CSF clearance — striking results in a uniformly fatal condition; single-center retrospective so flagged HIGH by NOVEL_TREATMENT rather than score. (Blood Adv; Lopedote P et al., City of Hope)

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• PMID-42905121 · Role of allogeneic HSCT in adults with mature T-cell lymphomas · 7/10 · Systematic Review (Cochrane series)
• PMID-42907308 · N-AVD or BrECADD for Advanced-Stage Classical Hodgkin Lymphoma · 6/10 · Treatment Innovation (Review)
• PMID-42904581 · USP7 inhibits FOXO1 activity in CLL cells enhancing cell survival · 5/10 · Drug Development (Lab; primary CLL cells + ibrutinib combo)
• PMID-42906183 · The Best Attainable Evidence for Cytoreduction in MPN-SVT · 5/10 · Treatment Innovation (Blood Adv evidence review)
• PMID-42905194 · CT Perfusion in differential diagnosis of GBM vs primary CNS lymphomas · 5/10 · Diagnostics

CBC-Based Diagnostics + ML

• PMID-42907972 · ClinNetDx: explainable AI for ALL detection using multi-modal CBC + image data · 5/10 · Diagnostics (public dataset; 98.1% accuracy)

Early Cancer Detection

• PMID-42907259 · Risk-stratified Prostate Cancer Screening in 2026: Blood- and Urine-based Biomarkers · 5/10 · Early Detection (Eur Urol Focus review)
• PMID-42905206 · Inferring tissue origin from cell-free DNA in metastatic cancer · 5/10 · Diagnostics (review, cfDNA tissue-of-origin methods)
• PMID-42907936 · ACR Lung-RADS: updates and future directions · 5/10 · Early Detection (Cancer Imaging review)

AI/ML in Clinical Diagnostics

• PMID-42906075 · AI-Based Delirium Risk Prediction vs 4AT-Score in 2002 trauma patients · 6/10 · Diagnostics (prospective; 87.3% vs 28% sensitivity)

Novel Therapeutics

• PMID-42906538 · Proteomic atlas of T cell exhaustion defines proteostatic collapse (Cell) · 6/10 · Treatment Innovation (RNF166 as immunotherapy target)
• PMID-42906872 · Redefining Cholangiocarcinoma Management: FGFR2/IDH1 targeted therapies and immunotherapy · 6/10 · Treatment Innovation

Cardiovascular-Metabolic

• PMID-42906947 · GLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment · 6/10 · Prevention (Obes Rev; GLP-1 RAs may reduce obesity-related cancer risk)
• PMID-42905300 · Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, Controversies · 5/10 · Drug Development

Aging / Longevity

• PMID-42902865 · Senokine Gas6 Promotes Aortic Valve Calcification via CaMKII-DRP1-Mitochondrial Vesicles · 4/10 · Prevention (Aging Cell; mechanistic aging-cardiovascular link)

Rare Diseases

• PMID-42906551 · CNS targeted AAV gene therapies: Recent advances and clinical insights (Cell Rep Med) · 7/10 · Treatment Innovation (CHOP; 4 FDA-approved CNS AAV therapies reviewed)
• PMID-42907672 · RF3 degradation enhances aminoglycoside readthrough at MECP2 nonsense mutations (Rett) · 5/10 · Drug Development (in vitro proof-of-concept)
• PMID-42906282 · Central monoamine dysfunction in Prader-Willi syndrome: mechanistic framework · 5/10 · Drug Development
• PMID-42906305 · Beyond inherited repeat length: somatic expansions in Huntington disease · 6/10 · Genomics/Precision Medicine
• PMID-42905937 · Head & Neck and Shoulder Desmoid-Type Fibromatosis: Ultra-Rare Locations (Cancer Med) · 6/10 · Other (multi-center French series)

💡 UNSOLICITED FINDS

PMID-42905121 · Role of allogeneic HSCT in adults with mature T-cell lymphomas · 7/10 · Systematic Review (Cochrane Database) Found via sentinel scan; matches Hematologic Malignancies watchlist. Cochrane-level evidence synthesis on allo-HSCT for mature T-cell lymphomas — highest design quality available for this rare, evidence-poor malignancy group. Scored and reported under hematologic malignancies.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 4
• Treatment Innovation: 8
• Diagnostics: 5
• Drug Development: 5
• Prevention: 2
• Genomics/Precision Medicine: 1
• Other: 1
• Public Health: 0

By evidence maturity:

• Exploratory: 12
• Validated: 10
• Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

*T5 top reviewed PMIDs were off-topic (metabolomics book chapter, varicose vein AI); articles matching T5 watchlist were captured under T1, T3, T6

By source type:

• Peer reviewed: 23
• Preprint: 0

Topics with zero 8+ articles this run (excluding flag-elevated): CBC/ML hematology, AI/ML diagnostics, Precision oncology, Novel therapeutics, Cardiovascular-metabolic, Aging/longevity, Rare diseases, Sentinel

🔧 RUN NOTES

• Window expansion: Not triggered. T1 alone returned 43 results; T9 returned 27 results; >5 relevant records found globally. No 48h expansion needed.
• Partial coverage: T4 (7/15), T5 (9/15), T6 (9/15) had the most unreviewed candidates. T7 and T8 had 4–5 unreviewed. Top candidates by relevance rank were prioritized. Recommend Attempt 2 to fetch remaining candidates if validator detects coverage gaps.
• False positive volume: T7 returned many Chinese-language cardiology journal articles (Zhonghua Xin Xue Guan Bing Za Zhi) matching "heart failure" and "obesity" broadly; T4 had many off-topic AI/imaging articles (fetal MRI segmentation, exon detection, stroke prognosis). Consider tighter T7 query for future runs.
• T5 query noise: The T5 "biomarker" query attracted many peripheral results; the watchlist-relevant articles from precision oncology were better captured under T1 (42902921 — AML genomic MRD) and T3 (42908017 — OC liquid biopsy). Recommend adding cancer-specific constraints to the T5 query.
• CBC/ML topic: Only 1 result in the window. This is consistent with prior run patterns when the hemorrhage/hematoma exclusions are applied; the single result (ClinNetDx ALL AI) was relevant. Consider expanding the fallback query window if this pattern persists.
• No data quality issues: All 10 PMID batches returned valid JSON from NCBI. No truncated responses or API errors.
• Rolling 7-day state unavailable for topic signal tracking (state.json last update: 2026-06-27; prior runs not loaded in this session).